5430642022-07-012022-09-305430642022-09-305430642022-03-315430642022-04-012022-09-305430642022-07-012022-09-30in-bse-fin:OtherExpenses1Member5430642022-07-012022-09-30in-bse-fin:OtherExpenses2Member5430642022-07-012022-09-30in-bse-fin:OtherExpenses3Member5430642022-04-012022-09-30in-bse-fin:OtherExpenses1Member5430642022-04-012022-09-30in-bse-fin:OtherExpenses2Member5430642022-04-012022-09-30in-bse-fin:OtherExpenses3Member5430642022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15430642022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares543064SUVENPHARNOTLISTEDINE03QK01018SUVEN PHARMACEUTICALS LIMITEDEquity2022-04-012023-03-312022-11-082022-11-01INRLakhsHalf yearlySingle segmentContract Development and Manufacturing2022-11-0811:30:002022-11-0812:30:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedConsolidated27840180001092000002893218000857501000021930002864780002934000120305000639052000190846300098475500009847550002498060001438600026419200007205630000000720563000-19180007186450000025456500012.832.83002.832.831) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th November, 2022. The above results have been subjected to limited review by the statutory auditors of the company. <BR> 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> 3) The consolidated financial results include the results of the wholly owned subsidiarIes Suven Pharma, Inc., USA and Casper Pharma Pvt Ltd, w.e.f. from 22nd April '2022. <BR> 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsiadary, Suven Pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our subsidiary. <BR> 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structuered deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec' 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar' 2022. <BR> 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for USD 20.50Min and has become a Wholly Owned Subsidiary of the Company w.e.f 22nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 each with a premium of Rs.70.00 per share for Rs.4172.92 Lacs. <BR> 8) The USFDA completed pre-approval inspecton at Casper Pharma formulations manufacturing fecility. The inspection was conducted from 25 through 29, July 2022. The audit was part of the agency's inspection for three applications filed and slated to be manufactured at this site. The audit completed successfuly with Zero observations and at the end of the inspection no form 483 was issed by USFDA and subsequently received EIR from USFDA. <BR> 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.2022-04-012022-09-30UnauditedConsolidated6172009000219531000639154000019848560000-1542200005523340001745000023535100012814230003917194000247434600002474346000656734000216280006783620000179598400000001795984000-383400017921500000025456500017.067.06007.067.06R & D expenses20746000Manufacturing Expenses461482000Other Expense156824000R & D expenses43069000Manufacturing Expenses884577000Other Expense3537770005910465000869237000079158500010300011709660001950005970000012308610003295200088352030003183079000327301700011115450006657010001842860001639000052361880008056870009224954000180601570002545650001477599100015030556000150305560002019860000540700020739300094092000563240000864725000703685000855559000220478000177972200017840800075994000130752000216487600030296010001806015700017450000-3489070001247495000000-154079000-1118200000-203446000002292630000301240005147000119415000-340590004682000000-63954000014483490000002286298000476064400000-2944000056822600065000416304300000000000720000193747600000000000000000000029440000074782000-18325340000000000005006300064130000203652000000-17450000-21104460002200630000220063000445638000665701000Items that will not be reclassified to profit or loss-2560000-2560000Items that will not be reclassified to profit or loss-5117000-5117000-642000-128300000